Safety and immunogenicity of the first Kazakh inactivated vaccine for COVID-19

This article describes the results of a preclinical safety and immunogenicity study of QazCovid-in®, the first COVID-19 vaccine developed in Kazakhstan, on BALB/c mice, rats, ferrets, Syrian hamsters and rhesus macaques (Macaca mulatta). The study’s safety data suggests that this immunobiological pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Nurpeisova, Ainur, Khairullin, Berik, Abitaev, Ruslan, Shorayeva, Kamshat, Jekebekov, Kuanish, Kalimolda, Elina, Kerimbayev, Aslan, Akylbayeva, Karligash, Abay, Zhandos, Myrzakhmetova, Balzhan, Nakhanov, Aziz, Absatova, Zharkinay, Nurabayev, Sergazy, Orynbayev, Mukhit, Assanzhanova, Nurika, Abeuov, Khairulla, Kutumbetov, Lespek, Kassenov, Markhabat, Abduraimov, Yergaly, Zakarya, Kunsulu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Influenza – Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621059/
https://www.ncbi.nlm.nih.gov/pubmed/35960911
http://dx.doi.org/10.1080/21645515.2022.2087412

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621059/
https://www.ncbi.nlm.nih.gov/pubmed/35960911
http://dx.doi.org/10.1080/21645515.2022.2087412

Ejemplares similares